Core Viewpoint - The company reported a revenue of 1,106.26 million yuan for the first three quarters of 2025, representing a year-on-year increase of 2.12%, while the net profit attributable to shareholders was 207.41 million yuan, up 26.24% year-on-year. However, the net profit for the third quarter decreased by 8.03% due to share-based payment expenses related to the 2025 equity incentive plan [5][6]. Financial Performance - The company achieved a revenue of 365.34 million yuan in the third quarter, a year-on-year increase of 9.80%, but the net profit attributable to shareholders was 65.45 million yuan, down 8.03% [5]. - Excluding the impact of share-based payment expenses, the net profit attributable to shareholders for the third quarter would have been 76.89 million yuan, reflecting an 8.1% year-on-year growth [5]. Business Operations - The orthopedic procurement execution remained stable, with domestic leading brands increasing their market share. The company is transforming its sales model, focusing on specialized departments to enhance marketing structure and improve clinical service levels, leading to sustained growth in revenue and sales [5][6]. - The joint product line saw a revenue of 273.22 million yuan in the first three quarters, a decrease of 9% year-on-year, while sales volume increased by 15% [5]. - The spinal minimally invasive product line reported a 3% increase in revenue and a 13% increase in sales volume year-on-year [6]. - The organization repair product line achieved sales revenue of approximately 163.69 million yuan, a year-on-year increase of 24%, with sales volume up 23% [6]. Shareholder Information - The company’s board of directors confirmed the authenticity and completeness of the quarterly report, ensuring no false records or significant omissions [2][9]. - The company’s major shareholders and their holdings were disclosed, with no changes reported in the top ten shareholders due to share lending activities [4]. Investment Activities - The company plans to invest 60 million yuan as a limited partner in a newly established partnership focused on the healthcare industry, with a total subscription amount of 300 million yuan [41][43]. - This investment is not classified as a related party transaction or a significant asset restructuring and has been approved by the board of directors without the need for shareholder meeting approval [41][45].

Group 1 - The core viewpoint of the article highlights the financial performance of Weigao Orthopedics (688161.SH) in the third quarter of 2025, showing a modest revenue growth and significant profit increase [1] Group 2 - The company achieved a total operating revenue of 1.106 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 2.12% [1] - The net profit attributable to shareholders of the parent company was 207 million yuan, reflecting a year-on-year increase of 26.24% [1] - The basic earnings per share stood at 0.52 yuan [1]

Core Insights - Weigao Group (01066) reported its subsidiary Weigao Orthopedics (688161.SH) third-quarter performance for 2024, achieving a revenue of 1.106 billion yuan, a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders was 207 million yuan, reflecting a year-on-year growth of 26.24%, with basic earnings per share at 0.52 yuan [1] - The announcement indicated that the overall execution of orthopedic bulk procurement remained stable, with domestic leading brands increasing their market share [1] Revenue and Profit Performance - The company recorded a revenue of 1.106 billion yuan for the first three quarters, marking a 2.12% increase compared to the previous year [1] - Net profit attributable to shareholders reached 207 million yuan, which is a 26.24% increase year-on-year [1] - Basic earnings per share stood at 0.52 yuan [1] Market and Operational Strategy - The orthopedic bulk procurement execution was reported to be stable during the reporting period [1] - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - This transformation aims to optimize and upgrade the marketing structure, enhance the professionalism and flexibility of the sales team, and significantly improve clinical service levels, leading to sustained growth in revenue and sales volume [1]

Core Viewpoint - Weigao Co., Ltd. reported a steady performance in its orthopedic segment, with revenue growth and significant profit increase in the third quarter of 2024 [1] Financial Performance - The company achieved a revenue of 1.106 billion yuan in the first three quarters, representing a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders reached 207 million yuan, marking a year-on-year increase of 26.24% [1] - Basic earnings per share were reported at 0.52 yuan [1] Market Dynamics - The overall execution of bulk purchasing in orthopedics remained stable during the reporting period [1] - The market share of leading domestic brands in the orthopedic sector continued to rise [1] Strategic Initiatives - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - Efforts to optimize and upgrade the marketing structure have been implemented, enhancing the professionalism and flexibility of the sales team [1] - These initiatives have led to sustained growth in revenue and sales volume across product lines [1]

Core Insights - Weigao Co., Ltd. reported a revenue of 1.106 billion yuan for the first three quarters of 2024, representing a year-on-year increase of 2.12% [1] - The net profit attributable to shareholders reached 207 million yuan, marking a year-on-year increase of 26.24% [1] - Basic earnings per share stood at 0.52 yuan [1] Revenue and Profit Performance - The company experienced stable execution of bulk procurement in the orthopedic sector during the reporting period [1] - The market share of leading domestic brands in the orthopedic field continued to rise [1] Strategic Initiatives - The company is undergoing a transformation in its sales model, focusing on professional departments for business unit division [1] - This transformation aims to optimize and upgrade the marketing structure, leading to increased specialization and flexibility within the sales team [1] - Enhanced professional service levels in clinical settings have contributed to sustained growth in revenue and sales volume across product lines [1]

威高骨科所属申万行业为：医药生物-医疗器械-医疗耗材。所属概念板块包括：医疗器械、中盘、融资 融券、医用耗材等。 从单季度指标来看，2025年第三季度公司毛利率为60.80%，同比下降5.21个百分点，环比下降7.52个百 分点；净利率为18.21%，较上年同期下降3.50个百分点，较上一季度下降2.22个百分点。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 2025年三季度，公司期间费用为4.56亿元，较上年同期减少5812.10万元；期间费用率为41.22%，较上 年同期下降6.24个百分点。其中，销售费用同比减少21.42%，管理费用同比增长38.09%，研发费用同比 减少7.89%，财务费用同比增长30.75%。 责任编辑：小浪快报 10月30日，威高骨科发布2025年三季报。报告显示，公司前三季度营业收入为11.06亿元，同比增长 2.12%；归母净利润为2.07亿元，同比增长26.24%；扣非归母净利润为1.94亿元，同比增长22.06%；基 本每股收益0 ...

第三届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688161 证券简称：威高骨科 公告编号：2025-042 山东威高骨科材料股份有限公司 一、董事会会议召开情况 山东威高骨科材料股份有限公司（以下简称"公司"）第三届董事会第十六 次会议于 2025 年 10 月 29 日以现场及通讯相结合的方式召开。本次会议应出席 董事 9 人，实际出席董事 9 人，会议由董事长陈敏女士主持，本次董事会会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法、有效。 二、董事会会议审议情况 1、审议通过《关于公司<2025 年第三季度报告>的议案》 公司董事会认为：公司《2025 年第三季度报告》的编制和审议程序符合法 律、法规、《公司章程》和公司内部管理制度的各项规定；公司《2025 年第三季 度报告》的内容与格式符合中国证券监督管理委员会和上海证券交易所的各项规 定，能够公允地反映公司报告期内的财务状况和经营成果。董事会及全体董事保 证公司《202 ...

Financial Performance - The company's operating revenue for Q3 2025 was CNY 365,344,702.03, representing a year-on-year increase of 9.80%[4] - The total profit for the period was CNY 76,887,856.58, showing a decrease of 13.00% compared to the same period last year[4] - The net profit attributable to shareholders was CNY 65,448,680.39, down 8.03% year-on-year[4] - The net profit after deducting non-recurring gains and losses was CNY 58,648,018.75, a decrease of 16.17% from the previous year[4] - The basic earnings per share for the period was CNY 0.16, a decrease of 11.11% year-on-year[4] - The weighted average return on equity was 1.61%, a decrease of 0.21 percentage points compared to the previous year[4] - The company achieved a total revenue of RMB 110,626.19 million for the first three quarters, representing a year-on-year growth of 2.12%[14] - The net profit attributable to shareholders for the same period was RMB 20,740.57 million, showing a year-on-year increase of 26.24%[14] - In Q3 alone, the company reported revenue of RMB 36,534.47 million, which is a 9.80% increase year-on-year, while net profit decreased by 8.03% to RMB 6,544.87 million[14] - Total operating revenue for the first three quarters of 2025 reached ¥1,106,261,911.75, an increase of 2.1% compared to ¥1,083,278,467.47 in the same period of 2024[22] - Net profit for the first three quarters of 2025 was ¥211,174,126.68, up 25.4% from ¥168,426,611.66 in the previous year[23] - Total comprehensive income amounted to CNY 211,174,126.68, an increase from CNY 168,426,611.66 in the previous period, representing a growth of approximately 25.4%[24] - Basic and diluted earnings per share increased to CNY 0.52 from CNY 0.41, reflecting a rise of 26.8%[24] Assets and Liabilities - The total assets at the end of the period amounted to CNY 5,093,265,583.29, reflecting a 2.94% increase from the end of the previous year[5] - The total assets of the company amounted to ¥5,093,265,583.29, compared to ¥4,948,035,237.87 in the previous period, indicating a growth of 2.9%[21] - The total liabilities increased to ¥1,006,444,803.73 from ¥984,785,361.90, marking a rise of 2.7%[20] - The equity attributable to shareholders rose to ¥4,073,322,439.44, up from ¥3,953,519,923.53, reflecting an increase of 3.0%[21] Cash Flow - The net cash flow from operating activities for the year-to-date was CNY 250,401,398.11, an increase of 31.90% compared to the previous year[4] - Net cash flow from operating activities was CNY 250,401,398.11, up from CNY 189,842,716.67, indicating a growth of 32%[28] - Cash inflow from investment activities totaled CNY 3,359,918,047.63, significantly higher than CNY 859,478,451.97 in the previous year[28] - Net cash flow from investment activities was negative at CNY -357,747,310.31, compared to CNY -5,178,898.97 previously, indicating increased investment outflows[28] - Cash and cash equivalents at the end of the period decreased to CNY 1,489,357,973.93 from CNY 1,924,464,930.46, a decline of approximately 22.6%[29] - Total cash outflow from financing activities was CNY 92,113,048.73, slightly higher than CNY 87,510,640.41 in the previous period[29] - The company received CNY 3,322,100,000.00 from the recovery of investments, a significant increase from CNY 840,000,000.00 in the prior year[28] - Cash received from other operating activities rose to CNY 57,891,432.49 from CNY 23,172,867.78, marking an increase of 149.5%[27] - The company reported a total cash inflow from operating activities of CNY 1,168,314,826.82, down from CNY 1,269,728,540.32, a decrease of approximately 8%[27] Research and Development - Research and development expenses totaled CNY 25,755,573.68, with a year-to-date decrease of 6.37%[5] - The ratio of R&D expenses to operating revenue was 7.05%, down 1.22 percentage points compared to the previous year[5] - Research and development expenses were ¥83,965,184.77, a decrease of 7.5% compared to ¥91,157,022.54 in the prior year[22] Sales and Marketing - The orthopedic product lines, particularly joint and spine minimally invasive products, showed significant growth, with joint product line sales revenue decreasing by 9% to RMB 27,322 million but with a 15% increase in volume[15] - The spine minimally invasive product line achieved a revenue growth of 3% year-on-year, with a 13% increase in sales volume[15] - The PRP product line generated approximately RMB 16,369 million in sales revenue, marking a 24% year-on-year increase, with a 23% increase in sales volume[16] - The company continues to optimize its sales model and enhance its marketing structure to improve clinical service levels and drive revenue growth[15] Cost Management - Total operating costs decreased to ¥863,391,351.16 from ¥909,362,061.83, representing a reduction of approximately 5.1%[22] - The company's gross profit margin improved, with operating profit increasing to ¥252,229,587.95 from ¥200,609,987.86, reflecting a growth of 25.7%[23] - The company reported a decrease in sales expenses to ¥292,240,112.98 from ¥371,892,305.06, a reduction of 21.4%[22]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：688161 证券简称：威高骨科 公告编号：2025-040 山东威高骨科材料股份有限公司 关于与私募基金合作投资公告 重要内容提示： 与私募基金合作投资的基本情况：山东威高骨科材料股份有限公司（以 下简称"公司"）拟与信金顺致私募基金管理（北京）有限公司、平湖鼎晟实业 有限公司、平湖市鑫翼东湖创业投资有限公司、浙江嘉创盛宇资产管理有限公司 共同投资设立嘉兴信威创盈股权投资合伙企业（有限合伙）（以下简称"合伙企 业"）（以市场监督管理机关最终核准登记为准）。合伙企业的认缴出资总额为 3 亿元，合伙企业的投资目标主要为医疗健康产业相关领域的处于成长期、成熟期 的企业/项目，与公司主营业务具有相关性。 相关风险提示 1、基金设立过程中存在可能因合伙人未能缴足认缴资金等客观原因，导致 基金未能成功募足资金的风险，实际募集及各方缴付出资情况可能存在不确定性。 投资金额、在投资基金中的占比及身份：公司作为有限合伙人，认缴出 资 6,000 万元，占合伙企业认缴出资总额的 20%。 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-041 山东威高骨科材料股份有限公司关于 拟聘请会计师事务所的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 变更会计师事务所的简要原因及前任会计师的异议情况：综合考虑公司 业务发展、审计工作需求等情况，为保证公司审计工作的独立性、客观性，公司 拟聘请德勤华永会计师事务所（特殊普通合伙）为公司 2025 年度财务报告和内 部控制审计机构。公司已就拟变更会计师事务所的相关情况与致同会计师事务所 （特殊普通合伙）进行充分沟通，其对变更事项无异议。 一、拟聘任会计师事务所的基本情况 （一）机构信息 1、基本信息 机构名称：德勤华永会计师事务所（特殊普通合伙） 成立日期：德勤华永会计师事务所（特殊普通合伙）的前身是1993年2月成 立的沪江德勤会计师事务所有限公司，于2002年更名为德勤华永会计师事务所有 限公司，于2012年9月经财政部等部门批准转制成为特殊普通合伙企业。 组织形式：特殊普通合伙 注册地址：上海市黄浦区延安东路222号30楼 首席 ...